Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases

Dig Dis Sci. 2018 Sep;63(9):2168-2171. doi: 10.1007/s10620-018-5039-y.

Authors

Stefano Fiorucci¹, Michele Biagioli², Eleonora Distrutti³

Affiliations

¹ Section of Gastroenterology, Department of Surgical and Biomedical Science, University of Perugia, Piazza Lucio Severi 1, S. Andrea delle Fratte, 06132, Perugia, Italy. Stefano.Fiorucci@unipg.it.
² Section of Gastroenterology, Department of Surgical and Biomedical Science, University of Perugia, Piazza Lucio Severi 1, S. Andrea delle Fratte, 06132, Perugia, Italy.
³ Azienda Ospedaliera di Perugia, Perugia, Italy.

PMID: 29611077
DOI: 10.1007/s10620-018-5039-y

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Biomarkers
Gastrointestinal Agents
Humans
Inflammatory Bowel Diseases*

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
Gastrointestinal Agents
vedolizumab